NextCure is a start-up company focused on discovering and developing next generation immunotherapy-based biologics for cancer and other immune-related disorders.

The company was founded by Dr. Lieping Chen, a pioneer in the field of immuno-oncology, with the support of the Yale Office of Cooperative Research.

The company is developing proprietary activity and receptor array systems which will enable the identification of specific interactions of human transmembrane proteins, providing the first complete map of cell-to-cell communication in the TME.